Opaleye Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Opaleye Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-250,000	Closed	-$3.05M	–	53
2015 Q4	$3.05M	Sell	250,000 -60,000	-19%	-$935K	1.28%	33
2015 Q3	$5.06M	Hold	310,000	–	–	2.49%	17
2015 Q2	$6.57M	Buy	310,000 +10,000	+3%	+$179K	2.61%	17
2015 Q1	$5.39M	Buy	300,000 +95,000	+46%	+$1.49M	2.5%	19
2014 Q4	$3.51M	Buy	+205,000	New	+$2.93M	1.77%	22

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.87B AUM 46.94% 1-Year Est. Return

FPC

Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Opaleye Management's AVDL Position: Q1 2016 in Review

Opaleye Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2016, closing a stake of 250,000 shares — an estimated $3.05M sold.

Opaleye Management first reported a position in AVDL in Q4 2014 and held it in 5 quarters. The position peaked at $6.57M in Q2 2015. 81 funds tracked by Wall St. Rank hold AVDL as of Q1 2016.

Opaleye Management reported no remaining Avadel Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Opaleye Management sold 250,000 Avadel Pharmaceuticals shares in Q1 2016, an estimated $3.05M.
Opaleye Management first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 5 quarters.
Opaleye Management's Avadel Pharmaceuticals position peaked at $6.57M in Q2 2015.
81 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2016.

Based on Opaleye Management's 13F filing for Q1 2016, filed 16 May 2016.